A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols Revised Protocol 09, incorporating Administrative Letter 01, 02, Amendments 01, 04, 05, 06, 07, 08, 09, 10 and 11 (version 10.0, dated 06-Dec-12) + administrative letter 03 dated 31-Jan-12

Trial Profile

A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols Revised Protocol 09, incorporating Administrative Letter 01, 02, Amendments 01, 04, 05, 06, 07, 08, 09, 10 and 11 (version 10.0, dated 06-Dec-12) + administrative letter 03 dated 31-Jan-12

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 08 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jan 2013 Planned End Date changed from 1 Apr 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 19 Oct 2012 Planned number of patients changed from 207 to 248 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top